Physician profile
Thomas H Salmon
NPI 1124124110
$12,766.18
in general payments reported to CMS, 2019-2025
55 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,658 · 2020: $1,970 · 2021: $1,710 · 2022: $2,250 · 2023: $2,169 · 2024: $1,387 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,178.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,807.37 | 2019-2025 | Botox, Duopa, Ubrelvy |
| Ucb, INC. | $930.29 | 2019-2025 | Briviact, Rystiggo |
| Biogen, INC. | $773.83 | 2019-2024 | Vumerity, Avonex, Plegridy |
| Emd Serono, INC. | $726.73 | 2019-2024 | Mavenclad |
| Genentech USA, INC. | $718.53 | 2019-2024 | Ocrevus, Enspryng |
| Pfizer INC. | $677.73 | 2021-2025 | |
| Grifols USA, LLC | $643.49 | 2021-2025 | Gamunex-C |
| Lilly USA, LLC | $613.38 | 2019-2024 | Emgality, Amyvid, Kisunla |
| Teva Pharmaceuticals USA, INC. | $581.84 | 2019-2023 | Austedo, Austedo Xr, Ajovy |
| Genzyme Corporation | $489.81 | 2019-2023 | |
| Lundbeck LLC | $435.34 | 2019-2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $405.71 | 2019-2023 | |
| Catalyst Pharmaceuticals, INC. | $402.18 | 2019-2024 | Firdapse |
| Allergan, INC. | $352.40 | 2019-2022 | |
| Amgen INC. | $345.53 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Salmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.